Antihyperlipidemic drug segmentation by type categorizes agents into statins, PCSK9 inhibitors, fibrates, bile‑acid sequestrants, omega‑3 fatty acid formulations, and emerging RNA‑based therapies. Statins remain the dominant class, contributing roughly 65 % of global sales due to their established efficacy, broad safety profile, and inclusion in most treatment algorithms. Within this class, high‑intensity statins such as atorvastatin and rosuvastatin capture the premium segment, while generic low‑ to moderate‑intensity products sustain volume growth in emerging markets. PCSK9 inhibitors, represented by monoclonal antibodies and newer siRNA agents, account for about 20 % of market value; their high per‑patient cost and restriction to high‑risk cohorts limit penetration but drive incremental revenue through specialty channels. Fibrates and bile‑acid sequestrants together hold roughly 8 % of sales, primarily serving patients with mixed dyslipidemia or statin intolerance. Omega‑3 fatty acid formulations and novel RNA‑based therapeutics each occupy less than 4 % of the market, yet they are strategic growth vectors because of ongoing clinical trials and potential label expansions. This type‑based taxonomy clarifies how each drug class underpins the overall antihyperlipidemic drug market and informs competitive positioning.
